Trump administration target CDC for coronavirus investigation

As the number of COVID-19 cases in the United States continues to rise, surpassing 2.3 million cases as of June 23, the Trump administration is taking aim at the CDC as a possible scapegoat. The administration is reportedly weighing whether to launch an in-depth evaluation of the agency to find and highlight perceived missteps in the fight against the pandemic, Politico reported.

The investigation would focus on the state-by-state death toll to look at how many Americans died from COVID-119 directly, rather than other factors, according to the report, which was based on interviews with 10 current and former senior administration officials and White House Republicans.

Trump has already criticized the World Health Organization, promising to withdraw the U.S. from the international organization. However, creating a “boogeyman” out of the CDC to shift the blame of the COVID-19 response in the U.S. away from Trump may be more challenging, according to one former administration official cited in Politico’s story. Actions to criticize and blame career health officials could backfire.

A White House official told Politico after publication of its story that an investigation is not intended to mire the CDC, but ensuring data is accurate and verified.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.